Table 4.

Prevalence of prodromal symptoms among 210 female and 179 male patients with ≥1 prodromal symptom.

	Female			Male
		Crude	Age Standardized		Crude	Age Standardized	Crude	Age Standardized
	n	%	%	n	%	%	P-Value	P-Value
Any symptom	210	34.5		179	35.9		0.64	0.84
Weakness	81	38.6	36.8	89	49.7	50.1	0.027	0.008
Clumsiness	20	9.6	11.1	35	19.6	19.9	0.005	0.016
Numbness	34	16.2	19.9	43	24	22.8	0.053	0.24
Seizure	7	3.3	2.9	7	3.9	3.4	0.76	0.78
Difficulty speaking	69	32.9	31.1	62	34.6	34.1	0.71	0.52
Difficulty walking	50	23.8	23.1	51	28.5	29.9	0.29	0.12
Headache	45	21.4	23.4	32	17.9	15.5	0.38	0.051
Change in behavior	26	12.4	11.6	17	9.5	10.6	0.37	0.76
Difficulty understanding	36	17.1	16.8	26	14.5	14.6	0.48	0.56
Nausea	14	6.7	7.2	17	9.5	10	0.30	0.32
Change in vision	33	15.7	16.6	21	11.7	10.9	0.26	0.10
Feels “funny”	21	10	9.6	10	5.6	5.8	0.11	0.16
Fatigue	12	5.7	5.5	13	7.3	7.4	0.53	0.46
Malaise	23	11	9.8	14	7.8	7.6	0.29	0.45
Other	90	42.9	42.3	67	37.4	38.3	0.28	0.42
Classic Cluster†	186	88.6	89.0	168	93.9	92.1	0.070	0.29
Somatic Cluster‡	159	75.7	75.3	116	64.8	65.2	0.019	0.030

^†Defined as the presence of ≥1 of the following prodromal symptoms: numbness, weakness, difficulty speaking, change in vision, difficulty walking, headache, clumsiness, or difficulty understanding.

^‡Defined as the presence of ≥1 of the following: headache, change in behavior, difficulty understanding, nausea, change in vision, feels “funny”, fatigue, malaise, or “other” prodromal symptom.